多柔比星心脏毒性防治策略研究进展

摘要

The utilization of d oxorubicin (DOX) is compromised by potential lethal cardiotoxicity in clinical application. Improving DOX efficacy in cancer cells while minimizing DOX-associated cardiotoxicity is in the forefront of research. Available methods at present include cardioprotective agents, DOX derivates and dosage schedules. This paper proposes new ideas on potential drug targets aiming at enhancing cancer therapy and cardioprotection simultaneously.%多柔比星(DOX)的临床应用受到潜在的致命心脏毒性的限制. 增强DOX的抗癌作用同时减少相关的心脏毒性一直是近年来研究的热点.目前可能的方法包括使用心脏保护药物、DOX衍生物以及改变给药方式.本文结合近年来的研究进展提出防治DOX心脏毒性的新思路,试图找到既能发挥抗癌功效、又能起到心脏保护作用的靶点和药物.